Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

← catalyst calendar

NCT06911632 · readout ≤ 651 d

Sponsored by Tempus AI (industry) · TEM — their whole pipeline →. With United Therapeutics.

Phase

Not applicable

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Diagnostic

Enrollment

900estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-07-23

actual

When the study began enrolling

Primary completion

May 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jul 2028

estimated

The whole study's end, after follow-up

First posted

2025-04-04

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Pulmonary Hypertension
Interstitial Lung Disease (ILD)

Interventions

Device: ECG-based AI Device - Results Returned to Investigator
Procedure: Echocardiogram and Right Heart Catheterization
Device: ECG-based AI Device - Results Not Returned to Investigator

Primary outcome

what the primary-completion date above is the date OF

Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.

measured Through study completion, approximately 6 months

Permalink · TEM's whole pipeline · Catalyst calendar · Every registered study · What changed